AstraZeneca Results Presentation Deck
Delivering on science-led
Selected key pipeline highlights since Q1 2023 results
innovation
10 regulatory approvals in major markets, including:
Lynparza (US)
prostate cancer (1st-line) (PROpel)
Enhertu (CN)
HER2-low breast cancer (3rd-line)
Farxiga (US)
HFPEF (DELIVER)
Beyfortus (US)
RSV (MELODY/MEDLEY)
Xigduo (CN)
type-2 diabetes (XR formulation)
APPENDIX | Pipeline Highlights
Oncology BioPharmaceuticals Rare Disease
Soliris (EU)
generalised myasthenia gravis
(refractory, children and adolescents)
Soliris (CN)
generalised myasthenia gravis
Ultomiris (EU, JP)
neuromyelitis opticaspectrum disorder
(CHAMPION-NMO)
Koselugo (CN)
neurofibromatosis type-1 with plexiform
neurofibromas (SPRINT)
34 HER2-low = human epidermal growth factor receptor 2-low; HFpEF = heart failure with preserved ejection fraction; RSV = respiratory syncytial virus; XR = extended release; CHMP = Committee for Medicinal Products for Human Use.
Collaboration partners: Daiichi Sankyo (Enhertu), Merck & Co., Inc. (Lynparza, Koselugo), Sanofi (Beyfortus).
AView entire presentation